Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1685-1692

  Von Laffert, Maximilian ^a   Warth, Arne ^b   Penzel, Roland ^b   Schirmacher, Peter ^b   Kerr, Keith M ^c   Elmberger, Göran ^d   Schildhaus, Hans Ulrich ^e   Büttner, Reinhard ^e   Lopez Rios, Fernando ^f   Reu, Simone ^g   Kirchner, Thomas ^g   Pauwels, Patrick ^h   Specht, Katja ⁱ   Drecoll, Enken ⁱ   Höfler, Heinz ⁱ   Aust, Daniela ^j   Baretton, Gustavo ^j   Bubendorf, Lukas ^k   Stallmann, Sonja ^l   Fisseler Eckhoff, Annette ^l   Soltermann, Alex ^m   Tischler, Verena ^m   Moch, Holger ^m   Penault Llorca, Frederique ⁿ   Hager, Hendrik ^o   Schäper, Frank ^p   Lenze, Dido ^a   Hummel, Michael ^a   Dietel, Manfred ^a   more..

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f HOSPITAL UNIVERSITARIO HM SANCHINARRO   (Spain)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k UNIVERSITY HOSPITAL BASEL   (Switzerland)

^l DR HORST SCHMIDT KLINIKEN   (Germany)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁿ CENTRE JEAN PERRIN   (France)

^o AARHUS UNIVERSITY HOSPITAL   (Denmark)

^p Bioptisches Institut Gemeinschaftspraxis für Pathologie   (Germany)

more..

Author keywords

Anaplastic lymphoma kinase gene rearrangement; Harmonization; Immunohistochemistry; Multicenter validation; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ARTICLE; CALIBRATION; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METHODOLOGY; NON SMALL CELL LUNG CANCER; OBSERVER BIAS; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TISSUE MICROARRAY; TRAINING; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84925745314     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000332     Document Type: Article

References (31)

1. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-1454.
2. Thunnissen E, Bubendorf L, Dietel M et al. Consensus statement on testing for EML4-ALK in non-small-cell carcinomas of the lung. Virch Arch 2012;461:245-257.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
4. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012.
5. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
7. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234.
8. Wong DW, Leung EL, So KK, et al; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
9. Just PA, Cazes A, Audebourg A, et al. Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 2012;76:309-315.
10. Camidge DR, Hirsch FR, Varella-Garcia M, Franklin WA. Finding ALK-positive lung cancer: what are we really looking for? J Thorac Oncol 2011;6:411-413.
11. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-5590.
12. von Laffert M, Warth A, Penzel R, et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013;81:200-206.
13. McLeer-Florin A, Lantuéjoul S. Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. J Thorac Dis 2012;4:240-241.
14. Savic S, Bubendorf L. Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012;56:611-621.
15. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-1571.
16. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-465.
17. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 2012;7:348-354.
18. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012;77:288-292.
19. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013;8:322-328.
20. To KF, Tong JH, Yeung KS, et al. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J Thorac Oncol 2013;8:883-891.
21. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26:1545-1553.
22. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011;6:1677-1686.
23. Penzel R, Schirmacher P, Warth A. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. J Thorac Oncol 2012;7:1198-1199.
24. Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014;9:631-638.
25. VENTANA ALK Scoring Interpretation Guide VENTANA ALK Scoring Interpretation Guide Copyright © 2012. Ventana Medical Systems, Inc. and Roche Diagnostics International, Inc. Available at: http://www.uclad.com/newsletters/ALK-LUNG-IHCINTERPRETATION-GUIDE.pdf. Accessed September 2014.
26. Nitta H, Tsuta K, Yoshida A, et al. New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC-in situ hybridization assay. J Thorac Oncol 2013;8:1019-1031.
27. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
28. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med 2013;137:828-860.
29. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009;54:12-27.
30. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012;7:e14-e16.
31. Camidge DR, Theodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012;118:4486-4494.